M&A Deal Summary

Acorda Therapeutics Acquires Biotie Therapies

On January 19, 2016, Acorda Therapeutics acquired life science company Biotie Therapies for 363M USD

Acquisition Highlights
  • This is Acorda Therapeutics’ 4th transaction in the Life Science sector.
  • This is Acorda Therapeutics’ 2nd largest (disclosed) transaction.
  • This is Acorda Therapeutics’ 1st transaction in Finland.

M&A Deal Summary
Date 2016-01-19
Target Biotie Therapies
Sector Life Science
Buyer(s) Acorda Therapeutics
Deal Type Add-on Acquisition
Deal Value 363M USD
Advisor(s) Guggenheim Securities (Financial)
Davis Polk & Wardwell
Hannes Snellman (Legal)

Target

Biotie Therapies

Turku, Finland
Biotie Therapies Corp. is a biopharmaceutical company primarily focused on developing therapeutics for central nervous system disorders. Its pipeline includes product candidates designed to address unmet medical needs in Parkinson’s disease and related dementia, other neurodegenerative indications and primary sclerosing cholangitis, an orphan fibrotic liver disease.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Acorda Therapeutics

Pearl River, New York, United States
Category Company
Founded 1995
Sector Life Science
Employees102
Revenue 118M USD (2023)
DESCRIPTION

Acorda Therapeutics is a biotechnology company developing therapies for multiple sclerosis and related neurological conditions such as spinal cord injury (SCI). Acorda Therapeutics was founded in 1995 and is headquartered in Pearl River, New York.

DEAL STATS #
Overall 4 of 4
Sector (Life Science) 4 of 4
Type (Add-on Acquisition) 4 of 4
Country (Finland) 1 of 1
Year (2016) 1 of 1
Size (of disclosed) 2 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-09-24 Civitas Therapeutics

Chelsea, Massachusetts, United States

Civitas Therapeutics, Inc. is a biopharmaceutical company focused on developing a robust pipeline of inhaled therapeutics with the clinically proven ARCUS® dry powder pulmonary delivery platform.

Buy $525M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-11-05 Acorda Therapeutics - Qutenza

Ardsley, New York, United States

Acorda Therapeutics, Inc. - Qutenza is a pain product. A single, 1-hour, localized treatment with this patch may provide at least 3 months of relief from for example post-shingles nerve pain.

Sell -
Mergr

Product

Company

Legal